
Why COVID Spikes in the Summer, and How to Stay Safe
"A couple of months ago, experts were uncertain about a summer wave," said Jodie Guest, PhD, an epidemiologist at Emory University in Atlanta who has tracked COVID since the start of the pandemic. "The low levels of respiratory illness in spring 2025 and stable variant landscape suggested a quiet summer."
But three key indicators now have COVID watchdogs sounding the alarm: a new virus strain, increasing wastewater levels, and emergency room visit upticks in parts of the U.S.
The CDC now lists the "COVID-19 epidemic trend" as growing or likely growing for more than half of U.S. states. The strongest indicators were seen in Arkansas, Hawaii, Illinois, Iowa, Kentucky, North Carolina, Ohio, Pennsylvania, Texas, and Virginia.
Here's what to know about summer COVID, and how to protect yourself – especially if you have a summer vacation or travel coming up.
I thought COVID was a big risk during flu season. Did something change? No, COVID has always had two waves, about six months apart – one in the summer and the other at the height of winter "respiratory season," when flu and respiratory syncytial virus (RSV) also rage.
The winter wave typically peaks sometime between "December and February, coinciding with colder weather and increased indoor gatherings," said Guest, senior vice chair of the Department of Epidemiology at Emory's Rollins School of Public Health. "Summer waves have occurred sporadically, often driven by new variants or waning immunity."
Here's when COVID peaked the past three summers:
2022: Around Aug. 1
2023: Around Sept. 30
2024: Around Aug. 31
This timing has prompted some experts to theorize that summer waves may be linked to people spending more time indoors with air conditioning during the height of summer heat.
Why are there two COVID waves, but influenza only spikes once per year? Some scientists point to rapid mutations and waning immunity from past infection or vaccination.
"A big chunk of people will get sick in a wave, and they'll have pretty good immunity to that particular variant, and that immunity is enough to sort of stop that wave in its tracks," said Emily Landon, MD, an infectious disease specialist at UChicago Medicine in Illinois. The virus then needs to change enough to evade existing immunity before another cycle starts back up.
A second theory suggests there are three distinct groups of people – a summer group, a winter group, and a group that gets infected twice a year. The idea is based on the idea that people vary in how long they're immune after infection, vaccination, or both.
Scientists still need more data to know for sure, "but the bottom line is we're certainly seeing a big increase in cases in the summer and a big increase of cases in the winter," Landon said.
Is this surge caused by the new variant? Yes, partly. NB.1.8.1 – or Nimbus – has been on the rise in Asia recently, and it now accounts for as many as 43% of new cases in the U.S., up from 24% at the beginning of June, according to CDC data. It's the variant known for a " razor blade" sore throat symptom, although it doesn't appear to cause more severe illness than other versions of the virus, Landon said.
This geographic pattern has become pretty set: A rising variant in Asia or Europe typically foreshadows a rise in the U.S., said Sabrina A. Assoumou, MD, MPH, an infectious disease doctor and professor at Boston University Chobanian & Avedisian School of Medicine.
Another regional clue: "We have typically seen that the [U.S.] rise in cases starts in the South," said Assoumou. She noted that some of the highest wastewater levels of SARS-CoV-2 (the virus that causes COVID) are in Florida and Alabama right now. "This is often followed by increases in other parts of the nation such as the Northeast."
How can I protect myself from summer COVID?
Make sure your vaccination is current. If you got a COVID shot last winter, you're probably good, Landon said. But if you're 65 or older, immunocompromised, or have a health condition that puts you at high risk – the CDC website maintains a list of qualifying conditions – ask your health care provider if you need a booster now. People with upcoming travel should consider a booster, too. Landon, who has rheumatoid arthritis and receives treatment that affects her immune system, just got a booster because she's going on vacation soon. "I want the best protection since I know that we're seeing the beginning of a summer spike," she said.
Remember that masks are still an effective tool. If you're traveling, wear a mask like an N-95, KN-95, or KF-94, and make it as snug as you can tolerate. Don't just wear it on the plane; wear it while lining up to board, too. It is OK to slip it down to sip a drink or eat a snack while in flight. "I would absolutely recommend that everyone wear a mask on an airplane," Landon said. "The last thing you want is even any kind of cold, let alone COVID, when you're on vacation."
Pack some COVID tests in your travel bag. If you know you have COVID, you can consider starting antiviral medication right away, which can reduce your risk of hospitalization.
Maybe bring a Paxlovid prescription too. If you're older or have a condition that puts you at high risk, ask your doctor to prescribe Paxlovid or another antiviral called molnupiravir to bring with you in case you get sick.
Ask sick people to stay home. If you're planning a summer party, Landon suggested adding a note to the bottom of the invite that says, "We have some high-risk people coming. If you're not feeling well, we'll take a pass and meet up with you another time when you're feeling better." Some people feel obligated to attend parties even when they aren't feeling well. "Letting them know that they're off the hook if they're sick and that you really don't want them to come if they're sick is a really important way that you can help protect your own health and help other people to do the right thing," Landon said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'
Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shed light on. Commenting on the company's recent earnings report results, Cramer said: 'Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we've long owned for the Charitable Trust… I'd say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook. wavebreakmedia/ Abbott (NYSE:ABT) is a healthcare company engaged in the research, development, manufacture, and marketing of a wide range of medical products. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
16 minutes ago
- Yahoo
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition
Eli Lilly and Company (NYSE:LLY) is one of the . Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of discovering, developing, manufacturing, and marketing innovative treatments across diseases like diabetes and in fields like oncology, immunology, and neuroscience. Some of the company's notable products, such as Humalog, Trulicity, Mounjaro, and Zepbound, are marketed in over 125 countries. The company is carrying on multiple studies and its latest updates include the Phase 2b clinical study titled 'A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa' and Phase 3 clinical study titled 'A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids.' Along with these studies, the company has a pipeline with potential drugs capable of generating more than $1 billion in annual revenue. Amid these studies, the company has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion. With this acquisition, Eli Lilly and Company (NYSE:LLY) aims to strengthen its positions in gene editing for cardiovascular conditions. With a beta of 0.44 signaling the company's resistance to market conditions, Eli Lilly and Company (NYSE:LLY) has a high anticipated 5-year EPS growth of 41.87%, making the stock a strong contender in our list. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None.
Yahoo
16 minutes ago
- Yahoo
Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
Milestone Highlights Rapid Hospital Adoption and Clinical Demand for Arrhythmia Insights that Improve Outcomes and Reduce Procedure Time SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States. "vMap has become an integral part of how I care for patients," said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. "It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation." As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA. "This milestone represents meaningful momentum," said Robert Krummen, CEO of Vektor Medical. "With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care." The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact. To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@